Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

BACKGROUND: Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Lu, Guo, Wei, Wang, Ye, Yan, Taiqiang, Ji, Tao, Xu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889565/
https://www.ncbi.nlm.nih.gov/pubmed/29625604
http://dx.doi.org/10.1186/s12885-018-4303-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889565/
https://www.ncbi.nlm.nih.gov/pubmed/29625604
http://dx.doi.org/10.1186/s12885-018-4303-z

Ejemplares similares